Clinical Trials
122 trialsTesting the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
SAFIR-ABC10
UNICANCER
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
University of California, Davis
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
Dana-Farber Cancer Institute
iNNOVATE
Virginia Commonwealth University
CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations
Mayo Clinic
Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC
University of Cincinnati
I-SPY
QuantumLeap Healthcare Collaborative
KNIGHTS
University of Maryland, Baltimore
ASCLEPIuS
University of Michigan Rogel Cancer Center
Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
University of Miami
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
M.D. Anderson Cancer Center
ANALLISA
MedSIR
NIRVANA-1
ARCAGY/ GINECO GROUP
HARMONY
Hoosier Cancer Research Network
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
NeuroTrials, LLC
Niraparib in Patients With Pancreatic Cancer
Dana-Farber Cancer Institute
Combination Therapy in Cancers With Mutations in DNA Repair Genes
University of California, San Francisco
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
St. Joseph's Hospital and Medical Center, Phoenix
A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
Abramson Cancer Center at Penn Medicine
PARPi-PANC
Centre Leon Berard
Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy
Jonsson Comprehensive Cancer Center
STAR
University of Oklahoma
Niraparib In Recurrent IDH 1/2 Gliomas
Massachusetts General Hospital
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
M.D. Anderson Cancer Center
Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer
OHSU Knight Cancer Institute
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
University of Alabama at Birmingham
Niraparib in Tumors Metastatic to the CNS
Massachusetts General Hospital
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
Niraparib/TTFields in GBM
Abramson Cancer Center at Penn Medicine
NIPAVect
Emory University
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
M.D. Anderson Cancer Center
ROCSAN
ARCAGY/ GINECO GROUP
Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA
Memorial Sloan Kettering Cancer Center
Parpvax
University of Pennsylvania
NADiR
Massachusetts General Hospital
UNITY
Massachusetts General Hospital
REPRESENTATION
Latin American Cooperative Oncology Group
ParpVax2
Abramson Cancer Center at Penn Medicine
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
AGO Study Group
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
Northwell Health
Niraparib + Dostarlimab + RT in Pancreatic Cancer
Massachusetts General Hospital
CAN-STAMP
University Health Network, Toronto
Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer
Mayo Clinic
ProTarget
Rigshospitalet, Denmark
A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers
University of Iowa